Formulated with care for preterm infants
Scientifically Developed, Tailored for the NICU
NeoMega36® is a Food for Special Medical Purposes (FSMP) formulated specifically to meet the nutritional needs of preterm infants. Developed to reflect the composition of human breast milk, it contains Arachidonic Acid (ARA) and Docosahexaenoic Acid (DHA) in a 2:1 ratio, supporting the development of normal visual function during a critical phase of early growth. The use of NeoMega36® is recommended as targeted nutritional enrichment for preterm infants, not as the sole source of nutrition. In clinical trials, the formulation was administered alongside human breast milk or suitable formulas.
Simple to Use, Aligned with Preterm Nutrition Guidelines
Each daily portion is just 0.4 ml per kg of body weight, delivering 100 mg/kg/day of ARA and 50 mg/kg/day of DHA. These amounts are aligned with the 2022 ESPGHAN recommendations on enteral nutrition for preterm infants, providing targeted nutritional support based on the latest clinical evidence. Breast milk alone often lacks sufficient DHA and ARA to meet these recommendations, highlighting the importance of supplementation in neonatal care.
Flexible Administration for NICU Feeding Protocols
NeoMega36® is also designed for flexibility and ease of use in neonatal intensive care settings. It can be administered orally or via nasogastric (NG) tube before the regular feed, allowing seamless integration into established feeding protocols. Clear and practical user instructions help ensure safe and accurate administration in busy clinical environments.
Combining evidence-based innovation with clinical usability, NeoMega36® offers healthcare professionals a reliable solution for supporting the nutritional needs of preterm infants, right from the start.
Rigorous Quality and Safety Standards in Neonatal Nutrition
At Neobiomics, we recognise that in the care of extremely preterm infants, precision, safety, and scientific integrity are paramount. NeoMega36® has been developed in alignment with these principles, offering a nutritional solution that adheres to rigorous quality and safety standards.
The manufacturing process is subject to stringent quality control protocols, ensuring batch-to-batch consistency and traceability. Our DHA and ARA formulation is supported by comprehensive stability and microbiological data, confirming its chemical integrity and microbial safety throughout its shelf life and in-use period. This robust evidence base enables clinicians to rely on NeoMega36® with confidence.
Preterm Infant Nutrition with Practical Administration
NeoMega36® is specifically designed for neonatal intensive care settings. Each 5 ml bottle allows for precise, hygienic administration tailored to the needs of fragile, low-weight infants. Once opened, the product remains microbiologically and chemically stable for up to seven days, ensuring both flexibility and safety during clinical use. NeoMega36® is sold in boxes of 6 bottles per box.
By upholding rigorous scientific standards and prioritising clinical practicality, NeoMega36® supports neonatal teams in delivering evidence-based nutritional care at a critical stage of infant development. We are proud to contribute to advancing health outcomes for the most vulnerable patients through high-quality innovation grounded in research.
